406 related articles for article (PubMed ID: 19023828)
21. Determination of 14 polycyclic aromatic hydrocarbons in mainstream smoke from U.S. brand and non-U.S. brand cigarettes.
Ding YS; Yan XJ; Jain RB; Lopp E; Tavakoli A; Polzin GM; Stanfill SB; Ashley DL; Watson CH
Environ Sci Technol; 2006 Feb; 40(4):1133-8. PubMed ID: 16572766
[TBL] [Abstract][Full Text] [Related]
22. Tobacco-specific nitrosamines in smokeless tobacco products marketed in India.
Stepanov I; Hecht SS; Ramakrishnan S; Gupta PC
Int J Cancer; 2005 Aug; 116(1):16-9. PubMed ID: 15756678
[TBL] [Abstract][Full Text] [Related]
23. Beyond the brotherhood: Skoal Bandits' role in the evolution of marketing moist smokeless tobacco pouches.
Hendlin YH; Veffer JR; Lewis MJ; Ling PM
Tob Induc Dis; 2017; 15():46. PubMed ID: 29270101
[TBL] [Abstract][Full Text] [Related]
24. Brand specific responses to smokeless tobacco in a rat lip canal model.
Schwartz JL; Brunnemann KD; Adami AJ; Panda S; Gordon SC; Hoffmann D; Adami GR
J Oral Pathol Med; 2010 Jul; 39(6):453-9. PubMed ID: 20642753
[TBL] [Abstract][Full Text] [Related]
25. Is low-nicotine Marlboro snus really snus?
Foulds J; Furberg H
Harm Reduct J; 2008 Feb; 5():9. PubMed ID: 18304348
[TBL] [Abstract][Full Text] [Related]
26. Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study.
Kotlyar M; Hertsgaard LA; Lindgren BR; Jensen JA; Carmella SG; Stepanov I; Murphy SE; Hecht SS; Hatsukami DK
Cancer Epidemiol Biomarkers Prev; 2011 Jan; 20(1):91-100. PubMed ID: 21068204
[TBL] [Abstract][Full Text] [Related]
27. Decreased levels of tobacco-specific N-nitrosamines in moist snuff on the Swedish market.
Osterdahl BG; Jansson C; Paccou A
J Agric Food Chem; 2004 Aug; 52(16):5085-8. PubMed ID: 15291479
[TBL] [Abstract][Full Text] [Related]
28. [Harm reduction strategy in tobacco control].
Gorini G
Epidemiol Prev; 2011; 35(3-4 Suppl 1):19-32. PubMed ID: 21926451
[TBL] [Abstract][Full Text] [Related]
29. Chemical profile of two types of oral snuff tobacco.
Brunnemann KD; Qi J; Hoffmann D
Food Chem Toxicol; 2002 Nov; 40(11):1699-703. PubMed ID: 12176096
[TBL] [Abstract][Full Text] [Related]
30. Potential reduced exposure products (PREPs) for smokeless tobacco users: clinical evaluation methodology.
Gray JN; Breland AB; Weaver M; Eissenberg T
Nicotine Tob Res; 2008 Sep; 10(9):1441-8. PubMed ID: 19023835
[TBL] [Abstract][Full Text] [Related]
31. Public education about the relative harm of tobacco products: an intervention for tobacco control professionals.
Biener L; Nyman AL; Stepanov I; Hatsukami D
Tob Control; 2014 Sep; 23(5):385-8. PubMed ID: 23481906
[TBL] [Abstract][Full Text] [Related]
32. Tobacco-specific N-nitrosamines and polycyclic aromatic hydrocarbons in cigarettes smoked by the participants of the Shanghai Cohort Study.
Yershova K; Yuan JM; Wang R; Valentin L; Watson C; Gao YT; Hecht SS; Stepanov I
Int J Cancer; 2016 Sep; 139(6):1261-9. PubMed ID: 27163125
[TBL] [Abstract][Full Text] [Related]
33. Determination of carcinogenic tobacco-specific nitrosamines in mainstream smoke from U.S.-brand and non-U.S.-brand cigarettes from 14 countries.
Wu W; Zhang L; Jain RB; Ashley DL; Watson CH
Nicotine Tob Res; 2005 Jun; 7(3):443-51. PubMed ID: 16085512
[TBL] [Abstract][Full Text] [Related]
34. An in Vitro Study of Constituents Released from Smokeless Tobacco Products into Human Saliva.
Guan S; Bush L; Ji H
J Anal Toxicol; 2022 Jul; 46(6):625-632. PubMed ID: 34155520
[TBL] [Abstract][Full Text] [Related]
35. Tobacco-Specific Nitrosamines in the Tobacco and Mainstream Smoke of U.S. Commercial Cigarettes.
Edwards SH; Rossiter LM; Taylor KM; Holman MR; Zhang L; Ding YS; Watson CH
Chem Res Toxicol; 2017 Feb; 30(2):540-551. PubMed ID: 28001416
[TBL] [Abstract][Full Text] [Related]
36. The need for regulation of carcinogenic N-nitrosamines in oral snuff.
Djordjevic MV; Brunnemann KD; Hoffmann D
Food Chem Toxicol; 1993 Jul; 31(7):497-501. PubMed ID: 8340028
[TBL] [Abstract][Full Text] [Related]
37. Oral mucosal changes and nicotine disposition in users of Swedish smokeless tobacco products: a comparative study.
Andersson G; Björnberg G; Curvall M
J Oral Pathol Med; 1994 Apr; 23(4):161-7. PubMed ID: 8046653
[TBL] [Abstract][Full Text] [Related]
38. Levels of toxins in oral tobacco products in the UK.
McNeill A; Bedi R; Islam S; Alkhatib MN; West R
Tob Control; 2006 Feb; 15(1):64-7. PubMed ID: 16436408
[TBL] [Abstract][Full Text] [Related]
39. In vitro study of nicotine release from smokeless tobacco.
Nasr MM; Reepmeyer JC; Tang Y
J AOAC Int; 1998; 81(3):540-3. PubMed ID: 9606918
[TBL] [Abstract][Full Text] [Related]
40. Global surveillance of oral tobacco products: total nicotine, unionised nicotine and tobacco-specific N-nitrosamines.
Stanfill SB; Connolly GN; Zhang L; Jia LT; Henningfield JE; Richter P; Lawler TS; Ayo-Yusuf OA; Ashley DL; Watson CH
Tob Control; 2011 May; 20(3):e2. PubMed ID: 21109685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
